Jonathan A Young, Arne Hinrichs, Stephen Bell, Delaney K Geitgey, Diana Hume-Rivera, Addison Bounds, Maggie Soneson, Zvi Laron, Danielle Yaron-Shaminsky, Eckhard Wolf, Edward O List, John J Kopchick, Darlene E Berryman
PURPOSE: Growth hormone receptor knockout (GHR-KO) pigs have recently been developed, which serve as a large animal model of Laron syndrome (LS). GHR-KO pigs, like individuals with LS, are obese but lack some comorbidities of obesity. The purpose of this study was to examine the histological and transcriptomic phenotype of adipose tissue (AT) in GHR-KO pigs and humans with LS. METHODS: Intraabdominal (IA) and subcutaneous (SubQ) AT was collected from GHR-KO pigs and examined histologically for adipocyte size and collagen content...
September 25, 2023: Pituitary
Huy Gia Vuong, Ian F Dunn
INTRODUCTION: Sparsely granulated somatotroph adenoma/tumor (SGST) is thought to be more clinically aggressive than densely granulated somatotroph adenoma/tumor (DGST). However, the literature is not entirely consistent as to the disparate demographic and behavioral features of these subtypes. In this study, we conducted a meta-analysis to further clarify the demographic, clinicopathological, prognostic, and molecular characteristics of SGST versus DGST. METHODS: We accessed two electronic databases to search for potential data...
September 21, 2023: Pituitary
Jung Park, Danielle Golub, Timothy G White, Marianne Ruelle, Eric T Quach, Kaiyun Yang, Harshal A Shah, Judd H Fastenberg, Mark B Eisenberg, Amir R Dehdashti
BACKGROUND: As endoscopic transsphenoidal approaches are more routinely selected for progressively larger pituitary adenomas with parasellar extension, understanding potential anatomical factors that limit resection and contribute to complications is becoming increasingly important for tailoring a surgical approach. This study aimed to reevaluate existing predictive tools for resectability in pituitary adenomas specifically with suprasellar extension, and furthermore identify any additional measurable features that may be more useful in preoperative planning...
September 15, 2023: Pituitary
Kaiyun Yang, Sabrina L Begley, Daniel Lynch, Vincent Ye, Jasleen Saini, Enrique Gutierrez, Jaclyn Vialet, Barbara-Ann Millar, Tatianna Conrad, Normand Laperriere, Mark Bernstein, Gelareh Zadeh, David B Shultz, Paul N Kongkham
PURPOSE: To understand the natural history and optimal treatment strategy for pituitary gland metastasis. METHODS: We performed both a retrospective chart review of patients treated at our institution and a scoping review of the topic. RESULTS: The retrospective review identified seven patients with an average age of 59.6 years. Primary histologies included breast cancer (4), melanoma (1), renal cell carcinoma (1), and sarcoma (1). Two patients had anterior pituitary endocrine dysfunction, one of whom was the only patient with visual symptoms...
September 12, 2023: Pituitary
Subbiah Sridhar, Bhagadurshah Rameez Raja, Raghavendran Priyanka, Sundari Natarajan, Sumathy Soundararajan, Vasanthiy Natarajan
PURPOSE: To analyze the clinical, hormonal, and radiological characteristics of Pituitary stalk interruption syndrome (PSIS) in children with growth hormone deficiency (GHD). METHODS: This is a prospective cross-sectional study, conducted over a period of three years in a short stature clinic of tertiary care referral hospital. 57 severe short stature children with proven GHD were included in the study. RESULTS: Among 57 children with GHD, 14 (24%) were diagnosed as PSIS...
September 11, 2023: Pituitary
Victoria R van Trigt, Ingrid M Zandbergen, Iris C M Pelsma, Leontine E H Bakker, Marco J T Verstegen, Wouter R van Furth, Nienke R Biermasz
PURPOSE: To describe care trajectories in patients with prolactinoma, aiming to clarify the rationale for surgery. METHODS: Retrospective observational cohort study of consecutive patients with prolactinoma undergoing surgery from 2017 to 2019 at the referral center (RC), prior to surgery being considered a viable treatment option (i.e. PRolaCT study). Demographics and clinical data (type and duration of pretreatment and surgical indications, goals, and outcomes) were collected from patient records...
September 10, 2023: Pituitary
E Jouanneau, F Calvanese, F Ducray, G Raverot
No abstract text is available yet for this article.
October 2023: Pituitary
Tomonori Sekizaki, Hiraku Kameda, Akinobu Nakamura, Saki Kuwabara, Hiroshi Nomoto, Kyu Yong Cho, Yukitomo Ishi, Hiroaki Motegi, Hideaki Miyoshi, Tatsuya Atsumi
PURPOSE: Cushing's disease (CD) results from autonomous adrenocorticotropic hormone (ACTH) secretion by corticotroph adenomas, leading to excessive cortisol production, ultimately affecting morbidity and mortality. Pasireotide is the only FDA approved tumor directed treatment for CD, but it is effective in only about 25% of patients, and is associated with a high rate of hyperglycemia. Neuromedin B (NMB), a member of the bombesin-like peptide family, regulates endocrine secretion and cell proliferation...
August 29, 2023: Pituitary
A Giustina, M M Uygur, S Frara, A Barkan, N R Biermasz, P Chanson, P Freda, M Gadelha, U B Kaiser, S Lamberts, E Laws, L B Nachtigall, V Popovic, M Reincke, C Strasburger, A J van der Lely, J A H Wass, S Melmed, F F Casanueva
PURPOSE: The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for Pituitary Tumor Centers of Excellence (PTCOEs) based on expert consensus. Aim of the study was to validate those previously proposed criteria through collection and evaluation of self-reported activity of several internationally-recognized tertiary pituitary centers, thereby transforming the qualitative 2017 definition into a validated quantitative one, which could serve as the basis for future objective PTCOE accreditation...
August 28, 2023: Pituitary
Billion Lisa, Verleye Arno, De Block Christophe, Van de Heyning Paul, De Herdt Carlien
PURPOSE: Giant prolactinomas are a rare entity, representing approximately 5% of all prolactinomas. A systematic review of 196 adult cases was performed. A comparison of the clinical, biochemical and radiological characteristics, management and therapeutic outcomes in men versus women is made. METHODS: A structured search was conducted using the term 'giant prolactinoma'. Following inclusion criteria were used: diameter ≥ 40 mm, prolactin levels > 1000 ng/ml and no concomitant GH/ ACTH secretion...
August 7, 2023: Pituitary
Ahmet Numan Demir, Cem Sulu, Zehra Kara, Serdar Sahin, Dilan Ozaydin, Ozge Sonmez, Fatma Ela Keskin, Necmettin Tanriover, Nurperi Gazioglu, Pinar Kadioglu
OBJECTIVE: Investigate the changes in the characteristics of presentation, in patients with acromegaly over a period of approximately half a century. METHODS: The medical records of patients diagnosed with acromegaly between 1980 and 2023 were retrospectively reviewed. The collected data were examined to assess any changes observed over the years and a comparison was made between the characteristics of patients diagnosed in the last decade and those diagnosed in previous years...
July 31, 2023: Pituitary
Alexander G Yearley, Eric J Chalif, Saksham Gupta, Joshua I Chalif, Joshua D Bernstock, Noah Nawabi, Omar Arnaout, Timothy R Smith, David A Reardon, Edward R Laws
PURPOSE: Pituitary carcinomas are a rare entity that respond poorly to multimodal therapy. Patients follow a variable disease course that remains ill-defined. METHODS: We present an institutional case series of patients treated for pituitary carcinomas over a 30-year period from 1992 to 2022. A systematic review was conducted to identify prior case series of patients with pituitary carcinomas. RESULTS: Fourteen patients with a mean age at pituitary carcinoma diagnosis of 52...
July 31, 2023: Pituitary
Alessandro Mondin, Filippo Ceccato, Giacomo Voltan, Pierluigi Mazzeo, Renzo Manara, Luca Denaro, Carla Scaroni, Mattia Barbot
CONTEXT: Cushing's disease (CD) is rare condition burdened by several systemic complications correlated to higher mortality rates. The primary goal of clinicians is to achieve remission, but it is unclear if treatment can also increase life expectancy. AIM: To assess the prevalence of cortisol-related complications and mortality in a large cohort of CD patients attending a single referral centre. MATERIALS AND METHODS: The clinical charts of CD patients attending a referral hospital between 2001 and 2021 were reviewed...
July 26, 2023: Pituitary
Amy J Wisdom, M Aiven Dyer, Nora K Horick, Beow Y Yeap, Karen K Miller, Brooke Swearingen, Jay S Loeffler, Helen A Shih
PURPOSE: The quality of life (QoL) impact of multidisciplinary treatment for patients with nonfunctioning pituitary macroadenomas (NFPMA) is unclear. We sought to investigate associations between patient factors, clinical data, and patient-reported QoL in patients with NFPMA. METHODS: Patients with treated NFPMA and > 1 year of follow up after transsphenoidal surgery (TSS) and with no evidence of progressive disease were evaluated utilizing the following patient-reported outcome measures: RAND-36-Item Health Survey, Multidimensional Fatigue Inventory, Cognitive Failures Questionnaire...
August 2023: Pituitary
Toshihiro Ogiwara, Satoshi Kitamura, Tetsuya Goto, Yu Fujii, Ken Yamazaki, Haruki Kuwabara, Akifumi Yokota, Hiromu Murase, Yoshiki Hanaoka, Atsushi Sato, Kazuhiro Hongo, Tetsuyoshi Horiuchi
PURPOSE: To satisfy the increasing demand for endoscopic endonasal approach (EEA) to treat pituitary tumors, especially in rural areas, the "mobile EEA" system, a visiting surgical service, has been established We report this unique system for maintaining community healthcare and evaluate the surgical results of mobile EEA. METHODS: A retrospectively acquired database of 225 consecutive cases of EEA at Shinshu University Hospital (i.e., "home EEA") and its affiliated hospitals (i...
July 21, 2023: Pituitary
Christopher S Hong, Hasan Alanya, Marcello DiStasio, Susan D Boulware, Ryan A Rimmer, Sacit Bulent Omay, E Zeynep Erson-Omay
PURPOSE: Pituitary adenomas commonly arise in patients with MEN1 syndrome, an autosomal dominant condition predisposing to neuroendocrine tumor formation, and typically diagnosed in patients with a relevant family cancer history. In these patients with existing germline loss of MEN1 on one allele, somatic loss of the second MEN1 allele leads to complete loss of the MEN1 protein, menin, and subsequent tumor formation. METHODS: Whole exome sequencing was performed on the tumor and matching blood under an institutional board approved protocol...
July 13, 2023: Pituitary
Andrew L Lin, Eliza B Geer, Nupur Lala, Gabrielle Page-Wilson, Rajiv Magge, Robert J Young, Viviane Tabar
INTRODUCTION: Aggressive prolactinomas are life-limiting tumors without a standard of care treatment option after the oral alkylator, temozolomide, fails to provide tumor control. METHODS: We reviewed an institutional database of pituitary tumors for patients with aggressive prolactinomas who progressed following treatment with a dopamine receptor agonist, radiotherapy and temozolomide. Within this cohort, we identified four patients who were treated with everolimus and we report their response to this therapy...
July 10, 2023: Pituitary
Cem Sulu, Nurdan Gul, Seher Tanrikulu, Sema Ciftci, Feyza Yener Ozturk, Betul Sarac, Elif Burcu Ersungur, Ezgi Tanriover, Serdar Sahin, Hande Mefkure Ozkaya, Burc Cagri Poyraz, Pinar Kadioglu
PURPOSE: To asses risk of new-onset impulse control disorders (ICDs) in patients with Cushing's disease (CD) who initiated cabergoline (CBG) and to determine frequency of ICDs in CBG-treated patients with CD. METHODS: This naturalistic observational study had prospective and cross-sectional arms which included patients at five referral centers based in Istanbul. Patients who were scheduled for CBG were assigned to prospective arm. These patients underwent neuropsychological tests (Barratt Impulsiveness Scale, Minnesota Impulsive Disorders Interview, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale, Go/No-Go Task, Iowa Gambling Task, and Short Penn Continuous Performance Test) for assessment of impulsivity and psychiatric evaluations at baseline, 3, 6, and 12 months of CBG treatment...
August 2023: Pituitary
Andrew L Lin, Viviane Tabar, Robert J Young, Eliza B Geer
PURPOSE: Papillary craniopharyngiomas can cause considerable morbidity due to mass effect and potential surgical complications. These tumors are known to harbor BRAF V600 mutations, which make them exquisitely sensitive to BRAF inhibitors. METHODS: The patient is a 59 year old man with a progressive suprasellar lesion that was radiographically consistent with a papillary craniopharyngioma. He was consented to an Institution Review Board-approved protocol, which permits sequencing of cell free DNA in plasma and the collection and reporting of clinical data...
August 2023: Pituitary
Khi Yung Fong, Mervyn Jun Rui Lim, Shuning Fu, Chen Ee Low, Yiong Huak Chan, Doddabele Srinivasa Deepak, Xinni Xu, Mark Thong, Swati Jain, Kejia Teo, Paul A Gardner, Carl H Snyderman, Vincent Diong Weng Nga, Tseng Tsai Yeo
BACKGROUND: Surgical resection is the main treatment for symptomatic nonfunctioning pituitary adenomas (NFPA). We aimed to analyze the impact of surgical approach, completeness of resection, and postoperative radiotherapy on long-term progression-free survival (PFS) of NFPA, using individual patient data (IPD) meta-analysis. METHODS: An electronic literature searched was conducted on PubMed, EMBASE, and Web of Science from database inception to 6 November 2022. Studies describing the natural history of surgically resected NFPA, with provision of Kaplan-Meier curves, were included...
August 2023: Pituitary
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.